vs
Side-by-side financial comparison of Biogen (BIIB) and RedHill Biopharma Ltd. (RDHL). Click either name above to swap in a different company.
Biogen is the larger business by last-quarter revenue ($2.3B vs $18.3M, roughly 124.2× RedHill Biopharma Ltd.). Biogen runs the higher net margin — -2.1% vs -63.8%, a 61.7% gap on every dollar of revenue. On growth, Biogen posted the faster year-over-year revenue change (-7.1% vs -14.7%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
RedHill Biopharma Ltd. is a specialty biopharmaceutical firm focused on developing and commercializing innovative therapeutics for gastrointestinal disorders, inflammatory conditions, and infectious diseases. It operates mainly in North American and European markets, delivering prescription treatments for unmet clinical needs and partnering with healthcare stakeholders to expand product access.
BIIB vs RDHL — Head-to-Head
Income Statement — Q4 2025 vs Q2 2022
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $18.3M |
| Net Profit | $-48.9M | $-11.7M |
| Gross Margin | 78.3% | 51.0% |
| Operating Margin | -2.5% | -49.9% |
| Net Margin | -2.1% | -63.8% |
| Revenue YoY | -7.1% | -14.7% |
| Net Profit YoY | -118.3% | 59.8% |
| EPS (diluted) | $-0.35 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.3B | — |
| Q4 25 | $-48.9M | — | ||
| Q3 25 | $466.5M | — | ||
| Q2 25 | $634.8M | — | ||
| Q1 25 | $240.5M | — | ||
| Q4 24 | $266.7M | — | ||
| Q3 24 | $388.5M | — | ||
| Q2 24 | $583.6M | — | ||
| Q1 24 | $393.4M | — |
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
| Q4 25 | -2.5% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 20.3% | — |
| Q4 25 | -2.1% | — | ||
| Q3 25 | 18.4% | — | ||
| Q2 25 | 24.0% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 15.8% | — | ||
| Q2 24 | 23.7% | — | ||
| Q1 24 | 17.2% | — |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $3.17 | — | ||
| Q2 25 | $4.33 | — | ||
| Q1 25 | $1.64 | — | ||
| Q4 24 | $1.82 | — | ||
| Q3 24 | $2.66 | — | ||
| Q2 24 | $4.00 | — | ||
| Q1 24 | $2.70 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $27.0M |
| Total DebtLower is stronger | $6.3B | — |
| Stockholders' EquityBook value | $18.3B | $-11.9M |
| Total Assets | $29.4B | $168.0M |
| Debt / EquityLower = less leverage | 0.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
| Q4 25 | $18.3B | — | ||
| Q3 25 | $18.2B | — | ||
| Q2 25 | $17.6B | — | ||
| Q1 25 | $17.0B | — | ||
| Q4 24 | $16.7B | — | ||
| Q3 24 | $16.4B | — | ||
| Q2 24 | $15.9B | — | ||
| Q1 24 | $15.2B | — |
| Q4 25 | $29.4B | — | ||
| Q3 25 | $29.2B | — | ||
| Q2 25 | $28.3B | — | ||
| Q1 25 | $28.0B | — | ||
| Q4 24 | $28.0B | — | ||
| Q3 24 | $28.3B | — | ||
| Q2 24 | $26.8B | — | ||
| Q1 24 | $26.6B | — |
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $511.9M | $-16.6M |
| Free Cash FlowOCF − Capex | $468.0M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $511.9M | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $160.9M | — | ||
| Q1 25 | $259.3M | — | ||
| Q4 24 | $760.9M | — | ||
| Q3 24 | $935.6M | — | ||
| Q2 24 | $625.8M | — | ||
| Q1 24 | $553.2M | — |
| Q4 25 | $468.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $134.3M | — | ||
| Q1 25 | $222.2M | — | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | — | ||
| Q2 24 | $592.3M | — | ||
| Q1 24 | $507.3M | — |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 24.0% | — | ||
| Q1 24 | 22.1% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
RDHL
Segment breakdown not available.
